Intellia Therapeutics Inc (NASDAQ:NTLA) shares saw unusually-strong trading volume on Wednesday . Approximately 241,521 shares were traded during trading, an increase of 19% from the previous session’s volume of 202,329 shares.The stock last traded at $17.90 and had previously closed at $18.76.

Several equities research analysts have issued reports on NTLA shares. Credit Suisse Group AG started coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price objective for the company. Jefferies Group initiated coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They set a “hold” rating and a $33.00 target price on the stock. Wedbush initiated coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They set an “outperform” rating and a $38.00 target price on the stock. Leerink Swann initiated coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They set a “market perform” rating and a $32.00 target price on the stock. Finally, Zacks Investment Research cut shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 3rd. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $35.50.

The stock’s 50-day moving average price is $19.91 and its 200 day moving average price is $23.31. The stock’s market cap is $645.03 million.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.